Biotech

All Articles

iTeos- GSK's TIGIT star presents relevant enhancement

.After declaring a period 3 launch based on good midstage outcomes, iTeos and also GSK are actually ...

More joint FDA can increase unusual disease R&ampD: record

.The FDA must be actually even more available and joint to unleash a rise in approvals of unusual il...

Zenas, MBX, Bicara head to Nasdaq in very hot time for biotech IPOs

.It is actually an extraordinarily active Friday for biotech IPOs, with Zenas BioPharma, MBX as well...

Atea's COVID antiviral fails to halt hospital stays in period 3

.Atea Pharmaceuticals' antiviral has stopped working another COVID-19 test, however the biotech stil...

Neurocrine's proposal to save schizophrenia possibility neglects

.Neurocrine Biosciences' mental illness system pivot has neglected. The biotech was incapable to dup...

Sanofi pays for $110M upfront for late-stage radioligand therapy

.Sanofi has actually created a late entrance to the radioligand gathering, paying out 100 million eu...

F 2G brings up $100M for 2nd attempt to receive brand new antifungal to market

.After F2G's very first attempt to obtain a new lesson of antifungal to market was derailed due to t...

Moderna targets $1.1 B in R&ampD investing cuts, falls 5 courses among earnings tensions

.Moderna has vowed to reduce R&ampD spending by $1.1 billion by 2027. The choice to retract the budg...

Sanofi's $80M bank on Fulcrum dystrophy medication finishes in stage 3 crash

.Merely 4 months after Sanofi bet $80 million in ahead of time cash money on Fulcrum Rehabs' losmapi...

Oncternal equity sinks 60% amid layoffs, trial terminations

.Cancer provider Oncternal Rehabs is folding all its professional tests and giving up staff, switchi...